Severe meningo-radiculo-nevritis associated with ipilimumab

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2407-2410

  Bompaire, Flavie ^a,b   Mateus, Christine ^c   Taillia, Hervé ^a,b   De Greslan, Thierry ^a   Lahutte, Marion ^a   Sallansonnet Froment, Magali ^a   Ouologuem, Madani ^a   Renard, Jean Luc ^a   Gorochov, Guy ^d,e   Robert, Caroline ^c   Ricard, Damien ^a,b  

^a University of Paris Descartes   (France)

^b Hôpital Inter Armées du Val de Grâce   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IPILIMUMAB; MEPREDNISONE; PLACEBO; PREDNISONE;

ADULT; AREFLEXIA; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DISEASE SEVERITY; DRUG MEGADOSE; FACIAL NERVE PARALYSIS; HUMAN; LYMPHOCYTIC MENINGOENCEPHALITIS; MALE; MELANOMA; MENINGITIS; MENINGORADICULONEVRITIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; QUADRIPLEGIA; SCROTUM DISORDER;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEUROTOXICITY SYNDROMES; SKIN NEOPLASMS;

EID: 84875531958     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9787-1     Document Type: Article

References (17)

1. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 19(363):711-723
2. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 30(364):2517-2526
3. Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab mono-therapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164
4. Bouchra A, Benbouazza K, Hajjaj-Hassouni N (2009) Guillain-Barre in a patient with ankylosing spondylitis secondary toulcerative colitis on infliximab therapy. Clin Rheumatol 28(Suppl 1):S53-S55
5. Turatti M, Tamburin S, Idone D et al (2010) Guillain-Barré syndrome after short-course efalizumab treatment. J Neurol 257:1404-1405
6. Shin IS, Baer AN, Kwon HJ et al (2006) Guillain-Barré and Miller Fisher syndromes occurring with tumour necrosis factor alpha antagonist therapy. Arthritis Rheum 54:1429-1434
7. Feinstein TM, Gibson MK, Argiris A (2009) Cetuximab-induced aseptic meningitis. Ann Oncol 20:1609-1610
8. Nagovskiy N, Agarwal M, Allerton J (2010) Cetuximab-induced aseptic meningitis. J Thorac Oncol 5:751
9. Kashyap AS, Kashyap S (2002) Infliximab-induced aseptic meningitis. Lancet 6(359):1252
10. Tarhini AA, Iqbal F (2010) CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 24(3):15-25
11. Eckert A, Schoeffler A, Dalle S et al (2009) Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 218:69-70
12. Hunter G, Voll C, Robinson CA (2009) Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 36:518-520
13. Yang JC, Hughes M, Kammula U et al (2007) Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30:825-830
14. Small EJ (2007) A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:1810-1815
15. Bettelli E, Oukka M, Kuchroo VK (2007) T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 8(4):345-350
16. Von Euw E, Chodon T, Attar N et al (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7:35
17. Callahan MK, Yang A, Tandon S et al. (Jun 9, 2011) Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. ASCO MEETING ABSTRACTS 2505